Intra-Arterial Thrombolysis After SUCCESSful Angiographic Recanalization in Acute Large Vessel Occlusion Stroke of the Anterior Circulation: the IA-SUCCESS Multicenter, Randomized Clinical Trial

Stroke is a leading cause of disability and mortality worldwide. Despite the clinical benefit of mechanical thrombectomy, 1 out of 2 patients treated are functionally independent at 90 days. Achieving the best possible angiographic reperfusion is a key determinant of clinical outcome in acute ischemic stroke patients with anterior circulation large vessel occlusion. Mechanical thrombectomy is standard treatment for large vessel occlusion stroke patients within 24. In the setting of successful (eTICI ≥2b), adjunct intra-arterial thrombolysis may be a promising therapeutic option allowing recanalization of distal arterial occlusions (not accessible to mechanical devices) and improvement of upstream brain reperfusion by targeting microvascular obstruction.
The IA-SUCCESS randomized trial aims to assess the clinical and safety of adjunct intra-arterial thrombolysis vs. no adjunct intra-arterial thrombolysis after successful angiographic reperfusion in patients with acute anterior circulation large vessel occlusion stroke.

Start Date03 Mar 2025

Sponsor / Collaborator

Centre Hospitalier Regional de Nancy

NCT06115070

/ Not yet recruitingPhase 4IIT

Intravenous Thrombolytic Therapy for Acute Ischemic Stroke Patients with Low NIHSS and Non-disabling Deficits

Minor stroke is considered an acute ischemic stroke (AIS) that has a National Institute of Health Stroke Scale (NIHSS) score ≤ 5 points. About 1/3 patients with mild stroke have poor prognosis, whether patients with this type undergo thrombolysis has been a controversial issue. A pooled analysis published in the Lancet in 2014 included 9 high-quality RCT studies of intravenous thrombolysis such as NINDS and IST3, and a total of 666 (10%) patients with mild stroke were included in the analysis. For mild stroke, the proportion of good prognosis in the control group and the alteplase group was 58.9% and 68.7% (OR 1.48, 95%Cl 1.07-2.06), respectively. Therefore, guidelines recommended alteplase thrombolytic therapy for patients with mild stroke. However, PRISMS, a randomized controlled trial of intravenous thrombolytic therapy for mild stroke published in 2018, found that alteplase intravenous thrombolytic therapy did not improve clinical outcomes compared with aspirin in patients with mild non-disabled stroke (90-day mRS 0-1 ratio 78.2% vs 81.5%), and the incidence of symptomatic intracranial hemorrhage was higher. However, a major limitation of the PRISMS study was that more than 85% of patients had numbness and dysarticulation, so this conclusion cannot be extrapolated to patients with other mild stroke symptoms. Moreover, due to the early termination of the sponsorship of this trial, the number of enrolled cases did not reach the pre-designed number, resulting in a serious decline in the authenticity of the study results. Symptoms and outcomes of minor stroke are important criteria for assessment. However, there is currently no uniform standard for the assessment of disability.
Both international and domestic guidelines recommend IVT with alteplase for minor disabling stroke within 4.5h, but not routinely recommend intravenous thrombolysis for minor nondisabling stroke within 4.5h. It is important to underline that strokes with low NIHSS scores are not necessarily nondisabling. Despite, patients with mild stroke symptoms are often excluded from IVT due to safety concerns potentially outweighing the putative benefits of recanalization therapy.
Therefore, the investigators developed a new definition to refine the disability assessment of stroke symptoms. The purpose of this study was to investigate whether AIS patients with NIHSS ≤ 5, a limb-related NIHSS item score of 0, and with any of the following NIHSS item ≥2: Best Gaze, Visual, Facial palsy, Limb ataxia, Sensory, Best language, Dysarthria, Extinction and Inattention, could benefit from intravenous thrombolysis.

Start Date01 Mar 2025

Sponsor / Collaborator

Second Affiliated Hospital Zhejiang University College of

IRCT20241023063472N1

/ SuspendedPhase 3IIT

Comparison of thrombolytic therapy with Alteplase and Tenecteplase for in patients with acute ischemic stroke in a clinical trial phase 3.

Start Date19 Feb 2025

Sponsor / Collaborator-

100 Clinical Results associated with Alteplase

100 Translational Medicine associated with Alteplase

100 Patents (Medical) associated with Alteplase

13,948

Literatures (Medical) associated with Alteplase

31 Dec 2025·Hospital Practice

Assessment of transition from use of alteplase to tenecteplase in the treatment of acute ischemic stroke in a large system of community hospitals

Article

Author: Hasse, Adam ; Poland, Russell E. ; Korwek, Kimberly ; Guy, Jeffrey

OBJECTIVEPharmacologic thrombolytic treatment for acute ischemic stroke has primarily been managed by intravenous alteplase. Tenecteplase is a variant that has been shown to be non-inferior to alteplase in clinical trials. In this study, we present a real-world assessment of patient outcomes with the facility-wide transition to the use of tenecteplase versus altepase for acute ischemic stroke in a large system of community hospitals in the United States.METHODSThis retrospective analysis assessed adult patients who received either alteplase or tenecteplase between 1 April 2020 and 31 March 2023. Propensity matching was used to estimate the covariate-adjusted association with outcomes of discharge expired/hospice, intracranial hemorrhage and readmission to a facility in the same healthcare system within 30, 60, or 90 days.RESULTSAmong 12,766 patients, gross mortality was 7.6% (n = 285) with tenecteplase and 8.2% (n = 739) with alteplase (p = 0.314); intracranial hemorrhage was 2.4% with either. The propensity match analysis found that the relative risk of mortality/hospice for patients given tenecteplase versus alteplase was 0.993 (95% CI: 0.848-1.162, p = 1.000). When limited to five facilities with the highest volume of thrombolytic use, there were no significant differences in outcomes. While the time from emergency department arrival to thrombolytic administration (door-to-needle) was shorter among patients receiving tenecteplase, there was no significant difference in the odds of mortality based on door-to-needle time.CONCLUSIONIn alignment with previous studies, these findings demonstrate the lack of potential harm with a transition from alteplase to tenecteplase in clinical practice for acute ischemic stroke patients treated in community hospitals.

31 Dec 2025·Hospital Practice

Modified infusion of recombinant tissue plasminogen activator in high-risk pulmonary thromboembolism with high bleeding risk: a case report

Article

Author: Hasin, Mohammad Hussein ; Ahmadi, Mostafa ; Shahri, Bahram ; Baradaran Rahimi, Vafa ; Yadollahi, Asal

High-risk pulmonary thromboembolism (PTE) is a form of venous thromboembolism that refers to severe obstruction of pulmonary vessels, which causes right ventricular failure and hemodynamic instability. High-risk PTE has a high mortality rate unless immediate reperfusion treatment is done. Systemic thrombolysis is recommended for patients with high-risk PTE. The approved regimen for high-risk PTE is the accelerated intravenous administration of recombinant tissue-type plasminogen activator (rtPA) 100 mg over 2 hours. Herein, we present a case of high-risk PTE in a 74-year-old woman with a high risk of bleeding due to a recent pelvic fracture and head trauma who was successfully treated with a slower infusion of 100 mg rtPA over 4 hours. The modified infusion rate of 100 mg rtPA over 4 hours is an effective regimen for thrombolysis in acute high-risk PTE. It might have a lower risk of bleeding complications, which makes it a good option for patients with high bleeding risk.

01 Jun 2025·Archivos Argentinos de Pediatria

Massive pulmonary thromboembolism in an adolescent with SARS-CoV-2 infection

Article

Author: Castillo Acevedo, Cecilia ; Acuña Aguirre, Carlos ; Chauriye Kuncar, Verónica ; Díaz Espejo, Piaignacia

Thromboembolic events incidence is low in pediatrics; high suspicion and explicit management algorithms are essential. We present a 12-year-old female patient with two weeks of dyspnea, orthopnea, and ankle edema. Tests showed metabolic acidosis, hyperlactatemia, elevated D-dimer, and positive SARS-CoV-2 CRP. The echocardiogram showed severe right ventricular dysfunction and supra-systemic pulmonary hypertension. Chest CT angiography showed extensive bilateral pulmonary thromboembolism. Anticoagulant therapy was started. She presented with hemodynamic instability. Adrenaline, norepinephrine, milrinone, and nitric oxide were started. The clinical picture was extremely severe in the first 24 hours. It was decided to perform systemic thrombolysis with alteplase, which led to an improvement. Cardiorespiratory stabilization and anticoagulation are the mainstays of therapy in massive pulmonary thromboembolism. Fibrinolytic therapy is used in selected high-risk cases. In this patient, systemic reperfusion therapy with alteplase was performed with no significant complications.

News (Medical) associated with Alteplase

06 Mar 2025

·www.drugs.com

FDA Approves TNKase for Acute Ischemic Stroke

THURSDAY, March 6, 2025 -- The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults. TNKase is delivered as a single five-second intravenous bolus. This is considerably faster than the standard of care, Activase (alteplase), which is administered as an intravenous bolus followed by a 60-minute infusion. Genentech, the manufacturer of TNKase, says a new 25-mg vial configuration will be available in the coming months. The approval is based on a study comparing TNKase to Activase in patients with acute ischemic stroke who presented with a disabling neurological deficit. Results show that TNKase was comparable to Activase in terms of efficacy and safety. Stroke affects more than 795,000 people each year in the United States. It is the leading cause of long-term disability and the fifth leading cause of death. Since brain damage occurs and progresses rapidly during an acute ischemic stroke, immediate, fast-acting medical care is vital. "Today's approval is a significant step forward and underscores our commitment to advancing stroke treatment options for patients," Levi Garraway, M.D., Ph.D., the chief medical officer and head of global product development at Genentech, said in a statement. "TNKase provides a faster and simpler administration, which can be critical for anyone who is dealing with an acute stroke." Approval of TNKase was granted to Genentech. More Information Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Drug Approval

05 Mar 2025

·pmlive.com

Roche’s Genentech granted FDA approval for TNKase in acute ischaemic stroke

Roche’s Genentech unit has received approval from the US Food and Drug Administration (FDA) for TNKase (tenecteplase) in acute ischaemic stroke (AIS). The drug, which has been authorised for use in adults, is now the first stroke medicine to be approved by the regulator in almost three decades. Stroke is the fifth leading cause of death and the leading cause of long-term disability in the US, affecting more than 795,000 people every year. An AIS occurs when the blood supply to part of the brain is blocked or reduced, preventing brain tissue from receiving oxygen and nutrients. TNKase is a tissue plasminogen activator, clot-dissolving, thrombolytic medicine that starts a biochemical reaction that can break down fibrin, a component of blood clots. Until now, the only FDA-approved medicine for AIS was Roche/Genentech’s Activase (alteplase), which is administered as an intravenous (IV) bolus followed by a 60-minute infusion. TNKase, delivered as a single five-second IV bolus, offers a faster and simpler administration compared to Activase. The drug is also already approved in the US to treat acute ST-elevation myocardial infarction in adults. The FDA’s latest decision was supported by results from a large multi-centre non-inferiority study demonstrating that TNKase is comparable to Activase in AIS patients in terms of safety and efficacy. Levi Garraway, Genentech’s chief medical officer and head of global product development, said: “[This] approval is a significant step forward and underscores our commitment to advancing stroke treatment options for patients. “TNKase provides a faster and simpler administration, which can be critical for anyone who is dealing with an acute stroke.” The authorisation comes less than a month after the FDA approved a tablet formulation of Roche’s spinal muscular atrophy treatment Evrysdi (risdiplam). Evrysdi was originally authorised by the US regulator in 2020 to treat the progressive neuromuscular disease in patients aged two months and older, before being granted expanded approval in 2022 for infants aged under two months. It is hoped that the tablet formulation, which can either be swallowed whole or dispersed in water and stored at room temperature, will provide more freedom and independence over the original oral solution.

Drug Approval

04 Mar 2025

·pipelinereview.com

FDA Approves Genentech’s TNKase®in Acute Ischemic Stroke in Adults

– TNKase ® (tenecteplase) is the first stroke medicine approved by the FDA in nearly 30 years – – Single five-second intravenous bolus provides faster and simpler administration than the approved standard-of-care – – Genentech has developed the only two FDA-approved medicines to treat acute ischemic stroke, TNKase and Activase ® (alteplase)– SOUTH SAN FRANCISCO, CA, USA I March 03, 2025 I Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke (AIS) in adults. This approval of TNKase marks Genentech’s second approval for stroke, reinforcing the company’s long-standing dedication to advancing stroke care as the developer of the only two FDA-approved medicines for AIS, TNKase and Activase ® (alteplase). TNKase is delivered as a single five-second intravenous (IV) bolus, a faster and simpler administration compared to the standard-of-care, Activase, which is administered as an IV bolus followed by a 60-minute infusion. Genentech will also be introducing a new 25 mg vial configuration in the coming months to support the approval of TNKase for AIS. “Today’s approval is a significant step forward and underscores our commitment to advancing stroke treatment options for patients,” said Levi Garraway, M.D., Ph.D., Genentech’s chief medical officer and head of Global Product Development. “TNKase provides a faster and simpler administration, which can be critical for anyone who is dealing with an acute stroke.” Stroke is the fifth leading cause of death, and the leading cause of long-term disability in the United States, affecting more than 795,000 people each year. During an AIS, brain damage occurs and progresses rapidly, meaning every moment without intervention leads to irreversible loss of nervous tissue, making immediate medical care crucial. The approval is based on a large multi-center non-inferiority study demonstrating that TNKase is comparable to Activase in AIS patients in terms of safety and efficacy. The AcT (Alteplase compared to Tenecteplase) trial compared TNKase to Activase in treating patients with acute ischemic stroke that presented with a disabling neurological deficit. This investigator-initiated study was conducted by the University of Calgary, was funded by the Canadian Institute of Health Research, and enrolled patients across 22 stroke centers in Canada. TNKase is also FDA approved for the treatment of acute ST-elevation myocardial infarction (STEMI) in adults. About TNKase ® (tenecteplase) TNKase ® (tenecteplase) is a tissue plasminogen activator, clot-dissolving, thrombolytic medicine. TNKase is administered as a single five-second intravenous bolus and starts a biochemical reaction that can break down fibrin, a component of blood clots. The most frequent adverse reactions associated with tenecteplase are bleeding and hypersensitivity. TNKase is now indicated for the treatment of acute ischemic stroke (AIS) in adults. The Dosage and Administration section of the label recommends to initiate treatment as soon as possible and within 3 hours after the onset of stroke symptoms. TNKase is also indicated to reduce the risk of death associated with acute ST-elevation myocardial infarction (STEMI). The Dosage and Administration section of the label recommends initiating treatment as soon as possible after the onset of STEMI symptoms. Alteplase and tenecteplase are marketed and supplied by Genentech in the United States and Canada under the brands Activase and TNKase; and by Boehringer Ingelheim in all other countries except the United States, Canada and Japan under the brands Actilyse® and Metalyse®. Important Safety Information Please see full Prescribing Information for additional Dosing and Administration and Important Safety Information. For more information, go to https://www.tnkase.com . About Activase ® (alteplase) Activase ® (alteplase) is indicated for treating patients with acute ischemic stroke (sudden stroke), which is caused by a blood clot in the brain’s blood vessels. Patients can receive Activase only if they begin treatment within 3 hours after their stroke symptoms start and only after bleeding in the brain has been ruled out. Important Safety Information Who should not be given Activase? Activase should not be used in patients who have: current bleeding in the brain; bleeding in the area between the brain and the thin tissues that cover the brain; active internal bleeding; recent (within 3 months) brain or spinal surgery or major head trauma; some brain tumor, an abnormal connection between veins and arteries in the brain, or an abnormal bulge in the wall of an artery that supplies blood to the brain; problems with blood clotting; or current severe uncontrolled high blood pressure. What are the possible serious side effects of Activase? Bleeding: The most common side effect with Activase is bleeding. Some patients may or may not benefit from Activase because of an increased risk of bleeding, including those with the following conditions: recent major surgery; disease of blood vessels in the brain; recent bleeding in the brain; recent digestive or urinary tract bleeding; recent trauma; uncontrolled high blood pressure; inflammation of the sac around the heart; infection of the inner lining of the heart and the heart valves; increased bleeding risk associated with liver or kidney problems; abnormal liver function; pregnancy; bleeding problems in the eyes; swelling and infection associated with blood clots; elderly patients; patients on blood thinning drugs. Allergic reaction (hypersensitivity): Allergic reactions including hives and severe or life-threatening allergic reactions can occur very quickly. Rare reports of death from severe allergic reactions have been reported. Swelling of the mouth and throat (angioedema) has been observed in patients treated for sudden stroke (acute ischemic stroke) and sudden heart attack (acute myocardial infarction). This occurred during and up to 2 hours after infusion of Activase. In many cases, patients were also taking angiotensin-converting enzyme inhibitors (a type of medication that can make blood vessels expand). Migrated blood clot (thromboembolism): The use of drugs to help dissolve blood clots can increase the risk of a clot breaking up and migrating in patients with high risk of clots in the left side of the heart, such as those with narrowed heart valves or some abnormal heart rhythms. Activase has not been shown to adequately treat deep vein blood clot in patients with pulmonary embolism. Blood clots that migrate can cause decreased blood flow to the area that they migrated to. A healthcare provider should evaluate this risk in these patients. Cholesterol Embolization: A plug of cholesterol that blocks an artery (cholesterol embolism) has been reported rarely in patients treated with all types of clot dissolving agents. This is a serious condition, which can be lethal, and is also associated with invasive medical procedures involving the arteries and veins. What is the most common side effect with Activase? The most common side effect with Activase is bleeding. Please see accompanying full Prescribing Information for Activase for additional important safety information. About Genentech in Stroke For decades, Roche and Genentech have been conducting neuroscience research and clinical trials aimed at exploring areas of the highest medical need. We have grown and advanced our neuroscience portfolio to be one of the most diverse and promising in the industry. From the approval of Activase in 1996, the first clot-dissolving medicine approved for the treatment of acute ischemic stroke and the standard-of-care in the United States, Genentech has a long-standing commitment to advancing stroke care. About Genentech Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com . SOURCE: Genentech

Drug Approval

100 Deals associated with Alteplase

External Link

KEGG	Wiki	ATC	Drug Bank
D02837	Alteplase	B01AD02 S01XA13	DB00009

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Myocardial Infarction	Japan	Mitsubishi Tanabe Pharma Corp.	29 Mar 1991
Myocardial Infarction	Japan	Kyowa Kirin Co., Ltd.	29 Mar 1991
Stroke	Japan	Mitsubishi Tanabe Pharma Corp.	29 Mar 1991
Stroke	Japan	Kyowa Kirin Co., Ltd.	29 Mar 1991
Acute Ischemic Stroke	United States	Genentech, Inc.	13 Nov 1987
Acute myocardial infarction	United States	Genentech, Inc.	13 Nov 1987
Pulmonary Embolism	United States	Genentech, Inc.	13 Nov 1987

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cerebral Hemorrhage	Discovery	China	Genentech, Inc.	30 Dec 2013
Catheter blockage	Discovery	Russia	Boehringer Ingelheim GmbH	01 Sep 2013
Venoocclusive disease	Discovery	Russia	Boehringer Ingelheim GmbH	01 Sep 2013
Acute Ischemic Stroke	Discovery	Japan	Mitsubishi Tanabe Pharma Corp.	01 Apr 2002
Acute Ischemic Stroke	Discovery	Japan	Kyowa Hakko Kogyo Co., Ltd.	01 Apr 2002
Brain Infarction	Discovery	Japan	Mitsubishi Tanabe Pharma Corp.	01 Apr 2002
Brain Infarction	Discovery	Japan	Kyowa Hakko Kogyo Co., Ltd.	01 Apr 2002
Acute myocardial infarction	Discovery	China	Boehringer Ingelheim GmbH	01 Mar 2001
Acute myocardial infarction	Discovery	South Korea	Boehringer Ingelheim GmbH	01 Mar 2001
Acute myocardial infarction	Discovery	Hong Kong	Boehringer Ingelheim GmbH	01 Mar 2001

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NEWS Manual	Not Applicable	Stroke	372	Alteplase	ghfewvnpte(hzolfkjvtf) = ssiritxyaa kmnscaoahe (cxhmmfegyv ) View more	Positive	07 Feb 2025
				Standard care (antiplatelet therapy)	ghfewvnpte(hzolfkjvtf) = fzngaozhar kmnscaoahe (cxhmmfegyv ) View more
NCT04806373 (CTgov)	Phase 4	Pleural Effusion	27	Talc Slurry Pleurodesis (Talc Slurry Pleurodesis (TSP) Plus Placebo)	lzsabvzkhv(cwhttcwfvr) = wtwbiindng dvwyolplyp (vdaekwsvfi, vidfioqumi - xmbvyjrxne) View more	-	11 Dec 2024
				Talc Slurry Pleurodesis+Cathflo Activase (Talc Slurry Pleurodesis (TSP) Plus Cathflo Activase)	lzsabvzkhv(cwhttcwfvr) = miphxksydc dvwyolplyp (vdaekwsvfi, rjlrohqgam - wtyrefbwih) View more
NCT04640194 (TRISTARDS, Pubmed \| Ann Intensive Care)	Phase 2/3	COVID-19	-	Alteplase (low-dose)	ftnguwkxrl(jshimdshtz) = ltppmfpfqh tsekxnjaei (pfeoomdvvr ) View more	Negative	10 Nov 2024
				Alteplase (Standard of care (SOC))	ftnguwkxrl(jshimdshtz) = dxxjrqtjeo tsekxnjaei (pfeoomdvvr )
NCT01827046 (MISTIE-III, Pubmed) Manual	Phase 3	Cerebral Hemorrhage	310	Minimally Invasive Surgery plAlteplasease (MIS+alteplase)	huutkbruel(nwylbinpez) = cgpgxvqcnm vvexdaiqnu (pgbwpyfgfg, 5.30)	Negative	26 Apr 2024
				alteplase (Standard Medical Care (SMC))	huutkbruel(nwylbinpez) = pujxqrvsii vvexdaiqnu (pgbwpyfgfg, 2.96)
NCT04640194 (TRISTARDS, CTgov)	Phase 2/3	COVID-19 \| Respiratory Distress Syndrome, Acute	104	Standard of care+Alteplase low dose (Part 1: Alteplase Low Dose)	hlrxvdcrmc(fliorrenrt) = kviwbmepbe tgefntktru (ubtyqmpsdi, bkwhpuwhcs - kkvhtouarg) View more	-	07 Mar 2024
				Standard of care+Alteplase high dose (Part 1: Alteplase High Dose)	hlrxvdcrmc(fliorrenrt) = cfhjpqbfow tgefntktru (ubtyqmpsdi, uufeeuqjen - gssulxwkuw) View more
FDA Manual	Not Applicable	Frostbite	47	buflomedil+aspirin+buflomedil (Groups A)	(sohtcffspv) = hrqdjlkkvr aoxykbploc (wpvbikvelo )	Positive	13 Feb 2024
				iloprost+aspirin+buflomedil (Groups B)	(sohtcffspv) = lxoivuhdxh aoxykbploc (wpvbikvelo )
EURETINA2023	Not Applicable	Retinal Artery Occlusion	-	Selective intra-ophthalmic arterial combined nimodipine and alteplase	bwfrknpmaa(fkbrdnoham) = There were also asymptomatic thromboembolic events in 2 patients (22.2%) after interventional procedure without any morbidity or mortality jsdvfocopl (furlfcgqft ) View more	-	05 Oct 2023
ANA2023	Not Applicable	Stroke	130	Tenecteplase	cmpyctlwwl(peapgwdejx) = khmmsitrqy vijvjjrbzf (sqrusqxfgr )	Positive	01 Sep 2023
				Alteplase	cmpyctlwwl(peapgwdejx) = gpigpizyua vijvjjrbzf (sqrusqxfgr )
ANA2023	Not Applicable	Acute Ischemic Stroke	148	Tenecteplase (TNK)	(dlhwfcrsnh) = hhtzduxvez oadlccyntf (xnpazntqdd ) View more	Positive	01 Sep 2023
				Alteplase (tPA)	(dlhwfcrsnh) = hpgnszicjt oadlccyntf (xnpazntqdd ) View more
ISTH2023	Not Applicable	Thrombosis	63	rt-PA	cxpdtckkaf(souoqrbzix) = hynzupdjdr bbqxxrzpzp (wwbcjlgyhr )	-	24 Jun 2023
				rt-PA + DNase-1	cxpdtckkaf(souoqrbzix) = qdzfafhrut bbqxxrzpzp (wwbcjlgyhr )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis